Krystal Biotech
KRYS · Biotechnology
$311.50
2.7%Roivant Sciences
ROIV · Biotechnology
$36.49
2.6%The short version
- Krystal Biotech is the larger business, with $389M of revenue in fiscal 2025 against $8.3M for Roivant Sciences, about 47 times as much.
- Krystal Biotech grew revenue faster (33.9%, against −71.6%).
- Krystal Biotech kept more of each dollar of sales as operating profit (41.5% operating margin, against −6,235.7% operating margin).
- Krystal Biotech turned more of its sales into free cash flow (48.6% FCF margin, against −9,183.5% FCF margin).
- Krystal Biotech earned a higher return on the capital invested in it (43.6%, against −62.6%).
| Latest fiscal year | KRYS · FY25 | ROIV · FY25 |
|---|---|---|
| Size | ||
| Market cap | $9.6B | $26.3B |
| Revenue | $389M | $8.3M |
| Free cash flow | $189M | −$759M |
| Net income | $205M | −$300M |
| Growth | ||
| Revenue growth | 33.9% | −71.6% |
| 5-year growth | — | −19.0% |
| Share count change | 0.7% | −4.4% |
| Profitability | ||
| Gross margin | — | — |
| Operating margin | 41.5% | −6,235.7% |
| Net margin | 52.6% | −3,629.2% |
| FCF margin | 48.6% | −9,183.5% |
| Return on capital | 43.6% | −62.6% |
| Return on equity | 18.9% | −6.5% |
| Balance sheet | ||
| Net debt | −$828M | −$4.3B |
| Net debt / EBITDA | −5.0x | — |
| Dividends and buybacks | $0.0M | $0.0M |
| Valuation & quality | ||
| P/E | 39.0x | — |
| Piotroski F-score | 5 | 1 |
FY16
KRYS —
ROIV —
FY17
KRYS —
ROIV —
FY18
KRYS —
ROIV —
FY19
KRYS —
ROIV —
FY20
KRYS —
ROIV $23.8M
FY21
KRYS $0.0M
ROIV $55.3M
FY22
KRYS $0.0M
ROIV $31.5M
FY23
KRYS $50.7M
ROIV $32.7M
FY24
KRYS $291M
ROIV $29.1M
FY25
KRYS $389M
ROIV $8.3M
KRYS
ROIV
FY16
KRYS —
ROIV —
FY17
KRYS —
ROIV —
FY18
KRYS —
ROIV —
FY19
KRYS —
ROIV —
FY20
KRYS —
ROIV −4,500.5%
FY21
KRYS —
ROIV −2,444.8%
FY22
KRYS —
ROIV −2,875.9%
FY23
KRYS −216.2%
ROIV 13,746.9%
FY24
KRYS 22.6%
ROIV −3,453.3%
FY25
KRYS 41.5%
ROIV −6,235.7%
KRYS
ROIV
FY16
KRYS −$1.3M
ROIV —
FY17
KRYS −$4.1M
ROIV —
FY18
KRYS −$11.7M
ROIV —
FY19
KRYS −$25.1M
ROIV —
FY20
KRYS −$40.9M
ROIV −$558M
FY21
KRYS −$116M
ROIV −$695M
FY22
KRYS −$154M
ROIV −$856M
FY23
KRYS −$101M
ROIV −$767M
FY24
KRYS $119M
ROIV −$844M
FY25
KRYS $189M
ROIV −$759M
KRYS
ROIV
FY16
KRYS —
ROIV —
FY17
KRYS —
ROIV —
FY18
KRYS —
ROIV —
FY19
KRYS —
ROIV —
FY20
KRYS —
ROIV —
FY21
KRYS −61.2%
ROIV —
FY22
KRYS −76.9%
ROIV −286.2%
FY23
KRYS −47.7%
ROIV —
FY24
KRYS 20.7%
ROIV —
FY25
KRYS 43.6%
ROIV −62.6%
KRYS
ROIV
Add another company
Compare up to four at once.
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.